Investors

Mindset is developing next-generation psychedelic medicines to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:

3 Patents filed on novel chemical structure and synthesis processes;

75 compounds synthesized with preclinical data demonstrating promising results; and

Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Stock Quote

Press Releases & News

Mindset Pharma Reaches Agreement to Manufacture Large Quantity of Pharmaceutical Grade Psilocybin Using Patent-Pending Synthesis Process

February 22, 2021

Read More

Mindset Pharma Added to North American Psychedelics Index

February 19, 2021

Read More

Mindset Announces Milestone in New Drug Program with Successful Proof-of-Concept Animal Studies of Its Patent-Pending Psilocybin-Inspired Drug Candidates

February 10, 2021

Read More